Related Experiment Video

Updated: Mar 14, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

684

[Actualities in the management of primary myelofibrosis]

Zsófia Simon1, Imelda Marton2, Zita Borbényi2

  • 1Klinikai Központ, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.

Orvosi Hetilap
|September 27, 2016
PubMed

Insights

Ruxolitinib, a JAK2 inhibitor, effectively reduces spleen size and symptoms in Philadelphia-negative myelofibrosis patients. This therapy offers disease modification and may improve survival for this rare blood cancer.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Primary myelofibrosis is a rare Philadelphia chromosome-negative chronic myeloproliferative neoplasm.
  • Characterized by cytopenias and hepatosplenomegaly, its etiology remains unknown, but pathology and prognosis understanding is advancing.
  • The JAK2 inhibitor ruxolitinib has been available in Hungary since 2015.

Purpose of the Study:

  • To summarize the evolving treatment approaches for myelofibrosis.
  • To highlight the efficacy and disease-modifying effects of ruxolitinib.

Main Methods:

  • Review of current literature and clinical practice regarding myelofibrosis treatment.
  • Analysis of ruxolitinib's impact on spleen volume, symptoms, and survival.

Main Results:

  • Ruxolitinib demonstrates high efficacy in reducing spleen volume and myelofibrosis-associated symptoms.
  • This JAK2 inhibitor exhibits disease-modifying effects, potentially improving patient life expectancy.

Conclusions:

  • Ruxolitinib represents a significant advancement in myelofibrosis treatment.
  • The availability of ruxolitinib has altered the therapeutic landscape for myelofibrosis, offering improved outcomes.
Keywords:
JAK2Philadelphia negative myeloproliferative neoplasmsPhiladelphia-negatív myeloproliferativ betegségWHO 2016calreticulinmyelofibrosisruxolitinib

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.5K

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
413
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
336